A Facebook roundup lines up CagriSema's REIMAGINE 2 numbers, with time in range rising from 52.3% to 88.0% by week 68, next to retatrutide's TRIUMPH-2 results.
Recap by typeshit. Post by Facebook on Facebook.
A Future Health & Medical Innovation panel weighs how much of the growing interest in peptides and exosomes is backed by evidence.
The aging doctor shares a headline saying new studies point to GLP-1 drugs slowing the biological clock, and notes himself that more research is needed.
An explainer on how GLP-1 drugs act on reward and craving in the brain, and the research testing them against alcohol, nicotine and other substance use.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
The FDA says retatrutide falls one alpha amino acid short. A biologic label would mean 12 years of exclusivity instead of 5, a later Medicare price clock and no compounding.
Johns Hopkins researchers report in Annals of Internal Medicine that the pill drew in new patients rather than pulling them away from injectable Wegovy or Zepbound.
Loading…